References:

1. Howe LR et al: Activation of the MAP kinase pathway by the protein kinase raf. Cell1992; 71:335-42.2. Langemeijer SM et al: Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009; 41:838-42.3. Schaub FX et al: Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2011; 115:2003-7.4. Langemeijer SMC et al: TET proteins in malignant hematopoiesis. Cell Cycle 2009; 4044-8.5. Gu TP et al:The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011; 477:606-10.